Finance entity
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Johnson & Johnson, the most common co-covered peer. The tracked stories average 2 original sources each. ICOTYDE appears in 1 tracked Finance story from September 8, 2026.
Last mentioned: 4d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Johnson & Johnson, the most common co-covered peer. The tracked stories average 2 original sources each. ICOTYDE appears in 1 tracked Finance story from September 8, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 14 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ICOTYDE. Shared-story counts are live from our verified record — not editorial picks.
Protagonist Therapeutics has authorized up to $300 million in buybacks, funded by an $849.5 million cash position and upcoming Takeda collaboration payments. Investors will watch how aggressively management repurchases shares and whether the program signals undervaluation or a lack of higher-return investments.
ICOTYDE is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
